Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2018-04-09 eCollection Date: 2018-06-01 DOI:10.2217/mmt-2017-0025

Daniel E Oliver, Vernon K Sondak, Tobin Strom, Jonathan S Zager, Arash O Naghavi, Amod Sarnaik, Jane L Messina, Jimmy J Caudell, Andy M Trotti, Javier F Torres-Roca, Nikhil I Khushalani, Louis B Harrison

{"title":"Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.","authors":"Daniel E Oliver, Vernon K Sondak, Tobin Strom, Jonathan S Zager, Arash O Naghavi, Amod Sarnaik, Jane L Messina, Jimmy J Caudell, Andy M Trotti, Javier F Torres-Roca, Nikhil I Khushalani, Louis B Harrison","doi":"10.2217/mmt-2017-0025","DOIUrl":null,"url":null,"abstract":"Aim: We assessed the role of adjuvant interferon on relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) in node-positive melanoma patients.Methods: We retrospectively reviewed 385 node-positive patients without distant metastatic disease treated from 1998 to 2015. The surgery was therapeutic lymph node dissection (LND, n = 86) or sentinel lymph node biopsy ± completion LND (n = 270). 128 patients (33.2%) received adjuvant interferon.Results: After a median follow-up of 70 months, interferon was associated with improved RFS (hazard ratio [HR]: 0.55; p < 0.001), DMFS (HR: 0.59; p < 0.001) and OS (HR: 0.61; p = 0.003), controlling for tumor and nodal stage, node size, sex, primary site, adjuvant therapy and extracapsular extension. In an exploratory age-matched comparison of patients treated with (n = 67) and without (n = 233) adjuvant immunotherapy, interferon still showed improved RFS, DMFS and OS.Conclusion: Adjuvant interferon appears to improve OS among node-positive melanoma patients in a modern experience, providing context for comparison in the adjuvant therapy landscape.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2018-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0025","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2017-0025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Aim: We assessed the role of adjuvant interferon on relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) in node-positive melanoma patients.

Methods: We retrospectively reviewed 385 node-positive patients without distant metastatic disease treated from 1998 to 2015. The surgery was therapeutic lymph node dissection (LND, n = 86) or sentinel lymph node biopsy ± completion LND (n = 270). 128 patients (33.2%) received adjuvant interferon.

Results: After a median follow-up of 70 months, interferon was associated with improved RFS (hazard ratio [HR]: 0.55; p < 0.001), DMFS (HR: 0.59; p < 0.001) and OS (HR: 0.61; p = 0.003), controlling for tumor and nodal stage, node size, sex, primary site, adjuvant therapy and extracapsular extension. In an exploratory age-matched comparison of patients treated with (n = 67) and without (n = 233) adjuvant immunotherapy, interferon still showed improved RFS, DMFS and OS.

Conclusion: Adjuvant interferon appears to improve OS among node-positive melanoma patients in a modern experience, providing context for comparison in the adjuvant therapy landscape.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

干扰素与淋巴结阳性皮肤黑色素瘤生存率提高相关:单一机构经验

目的:我们评估了辅助干扰素对淋巴结阳性黑色素瘤患者无复发生存期(RFS)、无远处转移生存期(DMFS)和总生存期(OS)的影响。方法:回顾性分析1998 - 2015年间385例无远处转移性肿瘤的淋巴结阳性患者。手术为治疗性淋巴结清扫(LND, n = 86)或前哨淋巴结活检±完成性淋巴结清扫(n = 270)。128例(33.2%)患者接受了辅助干扰素治疗。结果:中位随访70个月后，干扰素与RFS改善相关(风险比[HR]: 0.55;结论:在现代经验中，辅助干扰素似乎改善了淋巴结阳性黑色素瘤患者的OS，为辅助治疗领域的比较提供了背景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.